ERBB2 and breast cancer: In an open-label, multicenter, phase II clinical trial (ClinicalTrials.gov identifier: NCT02418689), a median PFS of 4.04 months was demonstrated when poziotinib was used in patients with refractory HER2-positive BC who had failed more than second-line HER2-targeted therapy [86,87].